Patents by Inventor Thomas Luther

Thomas Luther has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170110761
    Abstract: An ion transporting solvent for use with batteries can be improved by simultaneously shortening a phosphazene compound's pendent groups, eliminating most or all of the distal ion carriers, and randomizing the solvent molecules so as to intentionally disrupt symmetry to the maximum degree possible. The combination of these strategies dramatically improves battery performance to the point where the performance recorded is comparable to batteries using conventional organic solvents.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 20, 2017
    Applicant: PRINCESS ENERGY SYSTEMS, INC.
    Inventors: John L. Burba, III, Mason K. Harrup, Thomas A. Luther
  • Publication number: 20160294013
    Abstract: An ion transporting solvent for use with batteries can be improved by simultaneously shortening a phosphazene compound's pendent groups, eliminating most or all of the distal ion carriers, and randomizing the solvent molecules so as to intentionally disrupt symmetry to the maximum degree possible. The combination of these strategies dramatically improves battery performance to the point where the performance recorded is comparable to batteries using conventional organic solvents.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: PRINCESS ENERGY SYSTEMS, INC.
    Inventors: John L. Burba, III, Mason K. Harrup, Thomas A. Luther
  • Publication number: 20160285132
    Abstract: An ion transporting solvent for use with batteries can be improved by simultaneously shortening a phosphazene compound's pendent groups, eliminating most or all of the distal ion carriers, and randomizing the solvent molecules so as to intentionally disrupt symmetry to the maximum degree possible. The combination of these strategies dramatically improves battery performance to the point where the performance recorded is comparable to batteries using conventional organic solvents.
    Type: Application
    Filed: June 7, 2016
    Publication date: September 29, 2016
    Applicant: PRINCESS ENERGY SYSTEMS, INC.
    Inventors: John L. Burba, III, Mason K. Harrup, Thomas A. Luther
  • Patent number: 8461321
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: June 11, 2013
    Assignee: Wilex AG
    Inventors: Thomas Luther, Viktor Magdolen, Manfred Schmitt, Bernd Muehlenweg, Matthias Kotzsch
  • Publication number: 20120088162
    Abstract: An ion transporting solvent for use with batteries can be improved by simultaneously shortening a phosphazene compound's pendent groups, eliminating most or all of the distal ion carriers, and randomizing the solvent molecules so as to intentionally disrupt symmetry to the maximum degree possible. The combination of these strategies dramatically improves battery performance to the point where the performance recorded is comparable to batteries using conventional organic solvents.
    Type: Application
    Filed: May 13, 2011
    Publication date: April 12, 2012
    Inventors: Mason K. Harrup, Thomas A. Luther, John Leslie Burba
  • Patent number: 8129498
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with a moiety containing a carbonyl group, the substituted imidazole nitrogens being bonded to carbon of the carbonyl group. At least 85% of the nitrogens may be substituted. The carbonyl-containing moiety may include RCO—, where R is alkoxy or haloalkyl. The PBI compound may exhibit a first temperature marking an onset of weight loss corresponding to reversion of the substituted PBI that is less than a second temperature marking an onset of decomposition of an otherwise identical PBI compound without the substituted moiety. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may use more than 5 equivalents in relation to the imidazole nitrogens to be substituted.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: March 6, 2012
    Assignee: Battelle Energy Alliance, LLC
    Inventors: John R. Klaehn, Eric S. Peterson, Christopher J. Orme, Michael G. Jones, Alan K. Wertsching, Thomas A. Luther, Tammy L. Trowbridge
  • Patent number: 8063174
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with a moiety containing a carbonyl group, the substituted imidazole nitrogens being bonded to carbon of the carbonyl group. At least 85% of the nitrogens may be substituted. The carbonyl-containing moiety may include RCO—, where R is alkoxy or haloalkyl. The PBI compound may exhibit a first temperature marking an onset of weight loss corresponding to reversion of the substituted PBI that is less than a second temperature marking an onset of decomposition of an otherwise identical PBI compound without the substituted moiety. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may use more than 5 equivalents in relation to the imidazole nitrogens to be substituted.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: November 22, 2011
    Assignee: Battelle Energy Alliance, LLC
    Inventors: John R. Klaehn, Eric S. Peterson, Christopher J. Orme, Michael G. Jones, Alan K. Wertsching, Thomas A. Luther, Tammy L. Trowbridge
  • Publication number: 20110263813
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with a moiety containing a carbonyl group, the substituted imidazole nitrogens being bonded to carbon of the carbonyl group. At least 85% of the nitrogens may be substituted. The carbonyl-containing moiety may include RCO—, where R is alkoxy or haloalkyl. The PBI compound may exhibit a first temperature marking an onset of weight loss corresponding to reversion of the substituted PBI that is less than a second temperature marking an onset of decomposition of an otherwise identical PBI compound without the substituted moiety. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may use more than 5 equivalents in relation to the imidazole nitrogens to be substituted.
    Type: Application
    Filed: November 1, 2007
    Publication date: October 27, 2011
    Inventors: John R. Klaehn, Eric S. Peterson, Christopher J. Orme, Michael G. Jones, Alan K. Wertsching, Thomas A. Luther, Tammy L. Trowbridge
  • Publication number: 20110263727
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with a moiety containing a carbonyl group, the substituted imidazole nitrogens being bonded to carbon of the carbonyl group. At least 85% of the nitrogens may be substituted. The carbonyl-containing moiety may include RCO—, where R is alkoxy or haloalkyl. The PBI compound may exhibit a first temperature marking an onset of weight loss corresponding to reversion of the substituted PBI that is less than a second temperature marking an onset of decomposition of an otherwise identical PBI compound without the substituted moiety. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may use more than 5 equivalents in relation to the imidazole nitrogens to be substituted.
    Type: Application
    Filed: November 1, 2007
    Publication date: October 27, 2011
    Inventors: John R. Klaehn, Eric S. Peterson, Christopher J. Orme, Michael G. Jones, Alan K. Wertsching, Thomas A. Luther, Tammy L. Trowbridge
  • Patent number: 7772361
    Abstract: A PBI compound that includes imidazole nitrogens, at least a portion of which are substituted with an organic-inorganic hybrid moiety. At least 85% of the imidazole nitrogens may be substituted. The organic-inorganic hybrid moiety may be an organosilane moiety, for example, (R)Me2SiCH2—, where R is selected from among methyl, phenyl, vinyl, and allyl. The PBI compound may exhibit similar thermal properties in comparison to the unsubstituted PBI. The PBI compound may exhibit a solubility in an organic solvent greater than the solubility of the unsubstituted PBI. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may occur at about room temperature and/or at about atmospheric pressure. Substituting may use at least five equivalents in relation to the imidazole nitrogens to be substituted or, preferably, about fifteen equivalents.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 10, 2010
    Assignee: Battelle Energy Alliance, LLC
    Inventors: John R. Klaehn, Eric S. Peterson, Alan K. Wertsching, Christopher J. Orme, Thomas A. Luther, Michael G. Jones
  • Patent number: 7632898
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with an organic-inorganic hybrid moiety may be included in a separatory medium. At least 85% of the imidazole nitrogens may be substituted. The organic-inorganic hybrid moiety may be an organosilane moiety, for example, (R)Me2SiCH2— where R is selected from among methyl, phenyl, vinyl, and allyl. The separatory medium may exhibit an H2, Ar, N2, O2, CH3, or CO2 gas permeability greater than the gas permeability of a comparable separatory medium comprising the PBI compound without substitution. The separatory medium may further include an electronically conductive medium and/or an ionically conductive medium. The separatory medium may be used as a membrane (semi-permeable, permeable, and non-permeable), a barrier, an ion exchange media, a filter, a gas chromatography coating (such as stationary phase coating in affinity chromatography), etc.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: December 15, 2009
    Assignee: Battelle Energy Alliance, LLC
    Inventors: John R. Klaehn, Eric S. Peterson, Alan K. Wertsching, Christopher J. Orme, Thomas A. Luther, Michael G. Jones
  • Publication number: 20090202504
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Application
    Filed: June 30, 2008
    Publication date: August 13, 2009
    Applicant: WILEX AG
    Inventors: Thomas LUTHER, Viktor Magdolen, Manfred Schmitt, Bernd Muhlenweg, Matthias Kotzsch
  • Patent number: 7574113
    Abstract: Video data and audio data of multiplexed data are separated. Abstract video data is generated from the separated video data and abstract audio data is generated from the separated audio data. Then, the abstract video data and the abstract audio data are packed and a packed video and audio data management table is generated from packed video and audio data D2 and video and audio data synchronization information D3. The packed video and audio data management table comprehensively manages the packed video and audio data. Thus, data of various video formats, various audio formats and various multiplexing formats can be monistically managed.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: August 11, 2009
    Assignees: Sony Corporation, Sony Electronics Inc.
    Inventors: Daizoh Nagahara, Thomas Luther, Hiroaki Eto, Kanchan Ranade, David Wang, Tetsuya Yamamoto
  • Publication number: 20090012190
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with an organic-inorganic hybrid moiety. At least 85% of the imidazole nitrogens may be substituted. The organic-inorganic hybrid moiety may be an organosilane moiety, for example, (R)Me2SiCH2— where R is selected from among methyl, phenyl, vinyl, and allyl. The PBI compound may exhibit similar thermal properties in comparison to the unsubstituted PBI. The PBI compound may exhibit a solubility in an organic solvent greater than the solubility of the unsubstituted PBI. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may occur at about room temperature and/or at about atmospheric pressure. Substituting may use at least 5 equivalents in relation to the imidazole nitrogens to be substituted or, preferably, about 15.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 8, 2009
    Inventors: John R. Klaehn, Eric S. Peterson, Alan K. Wertsching, Christopher J. Orme, Thomas A. Luther, Michael G. Jones
  • Publication number: 20090012253
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with an organic-inorganic hybrid moiety. At least 85% of the imidazole nitrogens may be substituted. The organic-inorganic hybrid moiety may be an organosilane moiety, for example, (R)Me2SiCH2— where R is selected from among methyl, phenyl, vinyl, and allyl. The PBI compound may exhibit similar thermal properties in comparison to the unsubstituted PBI. The PBI compound may exhibit a solubility in an organic solvent greater than the solubility of the unsubstituted PBI. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may occur at about room temperature and/or at about atmospheric pressure. Substituting may use at least 5 equivalents in relation to the imidazole nitrogens to be substituted or, preferably, about 15.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 8, 2009
    Inventors: John R. Klaehn, Eric S. Peterson, Alan K. Wertsching, Christopher J. Orme, Thomas A. Luther, Michael G. Jones
  • Publication number: 20080188932
    Abstract: Embodiments include polymeric coatings formed from poly((perfluoro)organo)phosphazene-based materials. The coatings may be utilized to coat any suitable substrates, and in some embodiments may be utilized to coat surfaces of medical implants. The poly((perfluoro)organo)phosphazene-based materials may contain some fluorine-containing groups, and some crosslinkable moieties. The poly((perfluoro)organo)phosphazene-based materials may also contain some groups suitable for covalent bonding with surfaces of particular substrates. For instance, the poly((perfluoro)organo)phosphazene-based materials may include amine-containing groups for covalently bonding to urethane surfaces.
    Type: Application
    Filed: February 7, 2007
    Publication date: August 7, 2008
    Inventors: Mason K. Harrup, Frederick F. Stewart, Thomas A. Luther
  • Patent number: 7407751
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: August 5, 2008
    Assignee: Wilex AG
    Inventors: Thomas Luther, Viktor Magdolen, Manfred Schmitt, Matthias Kotzsch
  • Patent number: 7399468
    Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: July 15, 2008
    Assignee: Wilex AG
    Inventors: Thomas Luther, Martin Mueller, Sybille Albrecht, Viktor Magdolen, Olaf Wilhelm, Manfred Schmitt, Nadja Harbeck
  • Publication number: 20080096056
    Abstract: An ion transporting solvent maintains very low vapor pressure, contains flame retarding elements, and is nontoxic. The solvent in combination with common battery electrolyte salts can be used to replace the current carbonate electrolyte solution, creating a safer battery. It can also be used in combination with polymer gels or solid polymer electrolytes to produce polymer batteries with enhanced conductivity characteristics. The solvents may comprise a class of cyclic and acyclic low molecular weight phosphazenes compounds, comprising repeating phosphorus and nitrogen units forming a core backbone and ion-carrying pendent groups bound to the phosphorus. In preferred embodiments, the cyclic phosphazene comprises at least 3 phosphorus and nitrogen units, and the pendent groups are polyethers, polythioethers, polyether/polythioethers or any combination thereof, and/or other groups preferably comprising other atoms from Group 6B of the periodic table of elements.
    Type: Application
    Filed: August 30, 2007
    Publication date: April 24, 2008
    Inventors: Mason Harrup, Joseph Delmastro, Frederick Stewart, Thomas Luther
  • Patent number: 7309758
    Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with a moiety containing a carbonyl group, the substituted imidazole nitrogens being bonded to carbon of the carbonyl group. At least 85% of the nitrogens may be substituted. The carbonyl-containing moiety may include RCO—, where R is alkoxy or haloalkyl. The PBI compound may exhibit a first temperature marking an onset of weight loss corresponding to reversion of the substituted PBI that is less than a second temperature marking an onset of decomposition of an otherwise identical PBI compound without the substituted moiety. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may use more than 5 equivalents in relation to the imidazole nitrogens to be substituted.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: December 18, 2007
    Assignee: Battelle Energy Alliance, LLC
    Inventors: John R. Klaehn, Eric S. Peterson, Christopher J. Orme, Michael G. Jones, Alan K. Wertsching, Thomas A. Luther, Tammy L. Trowbridge